Walvax Biotechnology Co., Ltd. (300142.SZ)
CNY 13.07
(0.31%)
CNY 13.07
(0.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.77 Billion CNY | -13.1% |
| 2022 | 4.33 Billion CNY | 18.04% |
| 2021 | 3.67 Billion CNY | 105.28% |
| 2020 | 1.79 Billion CNY | 32.45% |
| 2019 | 1.35 Billion CNY | -31.77% |
| 2018 | 1.98 Billion CNY | -14.54% |
| 2017 | 2.31 Billion CNY | -17.21% |
| 2016 | 2.8 Billion CNY | -13.41% |
| 2015 | 3.23 Billion CNY | 17.36% |
| 2014 | 2.75 Billion CNY | -13.81% |
| 2013 | 3.19 Billion CNY | 149.66% |
| 2012 | 1.28 Billion CNY | 336.18% |
| 2011 | 293.61 Million CNY | -32.58% |
| 2010 | 435.51 Million CNY | 105.98% |
| 2009 | 211.43 Million CNY | 3.88% |
| 2008 | 203.54 Million CNY | 1.84% |
| 2007 | 199.85 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.16 Billion CNY | -20.04% |
| 2024 Q3 | 3.27 Billion CNY | 3.57% |
| 2024 Q1 | 3.95 Billion CNY | 4.85% |
| 2023 Q4 | 3.77 Billion CNY | -5.51% |
| 2023 Q1 | 4.24 Billion CNY | -2.18% |
| 2023 FY | 3.77 Billion CNY | -13.1% |
| 2023 Q2 | 4.18 Billion CNY | -1.42% |
| 2023 Q3 | 3.98 Billion CNY | -4.63% |
| 2022 FY | 4.33 Billion CNY | 18.04% |
| 2022 Q1 | 3.65 Billion CNY | -0.6% |
| 2022 Q2 | 4.23 Billion CNY | 16.02% |
| 2022 Q3 | 4.08 Billion CNY | -3.63% |
| 2022 Q4 | 4.33 Billion CNY | 6.21% |
| 2021 Q2 | 2.16 Billion CNY | 15.33% |
| 2021 FY | 3.67 Billion CNY | 105.28% |
| 2021 Q1 | 1.87 Billion CNY | 4.75% |
| 2021 Q4 | 3.67 Billion CNY | 25.11% |
| 2021 Q3 | 2.93 Billion CNY | 35.82% |
| 2020 FY | 1.79 Billion CNY | 32.45% |
| 2020 Q4 | 1.79 Billion CNY | 2.47% |
| 2020 Q3 | 1.74 Billion CNY | 51.07% |
| 2020 Q1 | 1.28 Billion CNY | -4.64% |
| 2020 Q2 | 1.15 Billion CNY | -10.28% |
| 2019 Q2 | 1.48 Billion CNY | -9.85% |
| 2019 Q1 | 1.64 Billion CNY | -17.06% |
| 2019 FY | 1.35 Billion CNY | -31.77% |
| 2019 Q3 | 1.44 Billion CNY | -2.24% |
| 2019 Q4 | 1.35 Billion CNY | -6.66% |
| 2018 Q4 | 1.98 Billion CNY | 2.94% |
| 2018 FY | 1.98 Billion CNY | -14.54% |
| 2018 Q3 | 1.92 Billion CNY | 10.26% |
| 2018 Q2 | 1.74 Billion CNY | -3.61% |
| 2018 Q1 | 1.81 Billion CNY | -21.89% |
| 2017 Q1 | 2.45 Billion CNY | -12.25% |
| 2017 FY | 2.31 Billion CNY | -17.21% |
| 2017 Q4 | 2.31 Billion CNY | 3.11% |
| 2017 Q3 | 2.24 Billion CNY | 1.18% |
| 2017 Q2 | 2.22 Billion CNY | -9.57% |
| 2016 Q2 | 4.02 Billion CNY | 1.18% |
| 2016 Q1 | 3.98 Billion CNY | 23.13% |
| 2016 FY | 2.8 Billion CNY | -13.41% |
| 2016 Q4 | 2.8 Billion CNY | -28.31% |
| 2016 Q3 | 3.9 Billion CNY | -3.04% |
| 2015 FY | 3.23 Billion CNY | 17.36% |
| 2015 Q3 | 2.97 Billion CNY | -4.35% |
| 2015 Q2 | 3.1 Billion CNY | 16.29% |
| 2015 Q4 | 3.23 Billion CNY | 8.86% |
| 2015 Q1 | 2.67 Billion CNY | -3.07% |
| 2014 Q1 | 3.39 Billion CNY | 6.24% |
| 2014 Q4 | 2.75 Billion CNY | -11.56% |
| 2014 FY | 2.75 Billion CNY | -13.81% |
| 2014 Q2 | 3.19 Billion CNY | -6.09% |
| 2014 Q3 | 3.11 Billion CNY | -2.33% |
| 2013 FY | 3.19 Billion CNY | 149.66% |
| 2013 Q4 | 3.19 Billion CNY | 32.26% |
| 2013 Q3 | 2.41 Billion CNY | 78.05% |
| 2013 Q2 | 1.35 Billion CNY | 6.77% |
| 2013 Q1 | 1.27 Billion CNY | -0.7% |
| 2012 Q3 | 586.03 Million CNY | 114.9% |
| 2012 FY | 1.28 Billion CNY | 336.18% |
| 2012 Q4 | 1.28 Billion CNY | 118.54% |
| 2012 Q1 | 241.77 Million CNY | -17.65% |
| 2012 Q2 | 272.7 Million CNY | 12.79% |
| 2011 Q3 | 254.65 Million CNY | 2.23% |
| 2011 Q2 | 249.09 Million CNY | 4.95% |
| 2011 Q1 | 237.34 Million CNY | -45.5% |
| 2011 Q4 | 293.61 Million CNY | 15.3% |
| 2011 FY | 293.61 Million CNY | -32.58% |
| 2010 Q2 | 387.89 Million CNY | 0.0% |
| 2010 Q4 | 435.51 Million CNY | 8.43% |
| 2010 FY | 435.51 Million CNY | 105.98% |
| 2010 Q3 | 401.65 Million CNY | 3.55% |
| 2009 FY | 211.43 Million CNY | 3.88% |
| 2008 FY | 203.54 Million CNY | 1.84% |
| 2007 FY | 199.85 Million CNY | 0.0% |